The Quantellect read.As of Nov 19, 2026, 6 active firms cover Myriad Genetics Inc: 1 rate it Buy or better, 4 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. The target range is very wide, $2.00 to $8.00 (about 4.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $4.02 sits 27% below the current $5.53. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.68 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Neutral
Strong Buy00%
Buy117%
Neutral467%
Sell117%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$4.02
-27.4% downside
Average target across 6 active firms as of Nov 19, 2026 vs $5.53 current
Highest Target$8.00
Average Target$4.02
Lowest Target$2.00
Detailed analyst forecasts for MYGN
Showing 1–7 of 7 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 1 of 6 active firms rate MYGN a Buy (4 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MYGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.31 – $-0.08 · 6 analysts · +89% YoY
Next period, 6 analysts expect Myriad Genetics Inc to earn $-0.17 a share (range $-0.31 – $-0.08), versus $-0.09 a year earlier. Full-year consensus is $-0.69, growing to $-0.68 the year after.
REVENUE · NEXT QUARTER
$190.6M
Range $160.4M – $206.4M · 6 analysts · -5% YoY
Revenue is expected to reach $190.6M (range $160.4M – $206.4M), -4.9% year-over-year. Full-year consensus is $786.0M, rising to $719.8M next year.
Top analysts covering Myriad Genetics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MYGN.
#1
Puneet Souda
Leerink Partners · Rank #30
Neutral
$9.00+62.7% to target
Overall win rate
57%
+ Follow
#2
MC
Mason Carrico
Stephens & Co. · Rank #178
Neutral
$3.00-45.8% to target
Overall win rate
40%
+ Follow
#3
SJ
Sung Ji Nam
Scotiabank · Rank #186
Neutral
$6.00+8.5% to target
Overall win rate
47%
+ Follow
#4
David Westenberg
Piper Sandler · Rank #314
Sell
$2.00-63.8% to target
Overall win rate
35%
+ Follow
#5
Matthew Sykes
Goldman Sachs · Rank #352
Buy
$8.00+44.7% to target
Overall win rate
38%
+ Follow
MYGN stock forecast FAQ
What is MYGN's average 12-month price target?+
The 6 active firms with a live target average $4.02 for Myriad Genetics Inc over the next 12 months, ranging from a $8.00 high to a $2.00 low, as of Nov 19, 2026.
Is MYGN stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 6 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 4 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MYGN?+
The Street-high target is $8.00 (Craig-Hallum), and the Street-low is $2.00 (Piper Sandler). The average of all 6 active-firm targets is $4.02.
How many active Wall Street firms cover MYGN?+
6 active firms have a recognized rating on Myriad Genetics Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MYGN?+
Among analysts who currently cover MYGN, Puneet Souda of Leerink Partners has the strongest overall Quantellect track record (Rank #30). Their current call is Neutral with a $9.00 target.
What is Myriad Genetics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.31 – $-0.08) across 6 analysts. Full-year EPS is projected at $-0.69, rising to $-0.68 the following year.
How much revenue is Myriad Genetics Inc expected to report next quarter?+
Consensus revenue is $190.6M (range $160.4M – $206.4M). Full-year revenue is projected at $786.0M, growing to $719.8M next year.
Have analysts been upgrading or downgrading MYGN lately?+
As of Nov 19, 2026, 1 of 6 active firms rate MYGN a Buy (4 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MYGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.